

Table 1. Baseline characteristics according to AOM exposure cohort in CPRD and BIFAP.

CPRD	Alendronate N=127121		Other biphosphonates N=29007		Strontium ranelate N=3045		Denosumab N=29		Teriparatide N=7		
	No.	%	No.	%	No.	%	No.	%	No.	%	
Females	101302	79.7	23763	81.9	2575	84.6	25	86.2	6	85.7	
Age at therapy initiation	Mean (sd)	73.4 (10.6)	73.3 (10.5)		79.3 (10.3)		78.1 (10.5)		72.9 (8.3)		
	50-59y	15249	12.0	3488	12.0	173	5.7	2	6.9	0	0.0
	60-69y	29537	23.2	6813	23.5	371	12.2	5	17.2	2	28.6
	70-70y	42037	33.1	9685	33.4	776	25.5	8	27.6	4	57.1
	>=80y	40298	31.7	9021	31.1	1725	56.7	14	48.3	1	14.3
Calendar start year	<2011	103,800	81.7	27,999	96.5	2,389	78.5	1	3.5	7	100
	≥2011	23,321	18.4	1,008	3.5	656	21.5	28	96.6	0	0
VTE before therapy initiation		6634	5.2	1578	5.4	159	5.2	3	10.3	0	0.0
Risk factors for VTE											
Venous insufficiency or phlebitis		19150	15.1	4273	14.7	467	15.3	7	24.1	1	14.3
HRT the year before therapy initiation		6036	4.8	1615	5.6	65	2.1	0	0.0	1	14.3
Recent fractures		7850	6.2	1624	5.6	492	16.2	3	10.3	0	0.0
Charlson index	none	68107	53.6	15687	54.1	1476	48.5	12	41.4	4	57.1
	mild	22625	17.8	5853	20.2	520	17.1	4	13.8	0	0.0
	moderate	18355	14.4	3699	12.8	499	16.4	3	10.3	1	14.3
	severe	18034	14.2	3768	13.0	550	18.1	10	34.5	2	28.6
Other comedication											
Other anti-osteoporosis medication		320	0.3	413	1.4	12	0.4	0	0.0	0	0.0
Calcium-Vitamin-D		31224	24.6	8178	28.2	1084	35.6	20	69.0	6	85.7
Glucocorticoids		51830	40.8	12058	41.6	818	26.9	13	44.8	2	28.6
Heparin		1483	1.2	235	0.8	46	1.5	2	6.9	0	0.0

Oral anticoagulant drugs	10641	8.4	2439	8.4	256	8.4	6	20.7	0	0.0	
BMI (Kg/m²)	<18.5	3082	2.4	718	2.5	133	4.4	1	3.45	0	0.0
	18.5-24.9	20701	16.3	4598	15.9	557	18.3	6	20.7	2	28.6
	25-29.9	16335	12.9	3429	11.8	316	10.4	4	13.8	2	28.6
	30-34.9	7246	5.7	1473	5.1	144	4.7	5	17.2	0	0.0
	35-39.9	2272	1.8	481	1.7	27	0.9	2	6.9	0	0.0
	>=40	961	0.8	199	0.7	10	0.3	0	0.0	0	0.0
	Missing	76524	60.2	18109	62.43	1858	61.0	11	37.9	3	42.9
Current smoker	No	56179	44.2	12610	43.5	1418	46.6	13	44.8	4	57.1
	Yes	11222	8.8	2407	8.3	217	7.1	1	3.5	0	0.0
	Missing	59720	47.1	13990	48.2	1410	46.3	15	51.7	3	42.9
BIFAP	Alendronate N=36182		Other biphosphonates N=37594		Strontium ranelate N=7978		Denosumab N=293		Teriparatide N=1287		
	No.	%	No.	%	No.	%	No.	%	No.	%	
Females	32348	89.4	33732	89.7	7191	90.1	264	90.1	1037	80.6	
Age at therapy initiation	Mean (sd)	68.67; SD 10.13		68.19; SD 10.09		68.83; SD 10.58		70.90; SD 10.71		73.00; SD 9.78	
	50-59y	8200	22.7	9048	24.1	1878	23.5	51	17.4	151	11.7
	60-69y	10387	28.7	11069	29.5	2215	27.8	86	29.4	273	21.2
	70-70y	11948	33.0	11963	31.8	2452	30.7	77	26.3	505	39.2
	>=80y	5647	15.6	5514	14.7	1433	18.0	79	27.0	358	27.8
Calendar start year	<2011	33948	93.8	34730	92.4	7016	88.0	0	-	856	66.5
	≥2011	2234	6.2	2864	7.6	962	12.1	293	100.0	431	33.5
VTE before therapy initiation	506	1.4	505	1.3	98	1.2	5	1.7	40	3.1	
Risk factors for VTE											
Cancer	3603	10.0	3871	10.3	831	10.4	50	17.1	150	11.7	
Peripheral arterial disease	416	1.2	442	1.2	102	1.3	4	1.4	40	3.1	
Venous insufficiency or phlebitis	6957	19.2	7579	20.2	1762	22.1	88	30.0	293	22.8	

HRT the year before therapy initiation	1098	3.0	1056	2.8	198	2.5	0	0.0	9	0.7
Recent fractures	2821	7.8	2807	7.5	820	10.3	43	14.7	268	20.8
Other co-medication										
Other anti-osteoporosis medication	2698	7.5	2733	7.3	610	7.7	39	13.3	191	14.8
Calcium-Vitamin-D	12292	34.0	13719	36.5	2709	34.0	193	65.9	542	42.1
Glucocorticoids	6496	17.8	7761	20.6	1485	18.6	94	32.1	364	28.3
Heparin	4292	11.9	4664	12.4	1225	15.4	53	18.1	343	26.7
Oral anticoagulant drugs	1783	4.9	1786	4.8	361	4.5	15	5.1	135	10.5
BMI (Kg/m ²) <18.5	111	0.3	106	0.3	18	0.2	2	0.7	9	0.7
18.5-24.9	3200	8.8	3122	8.3	629	7.9	31	10.6	109	8.5
25-29.9	6094	16.8	6242	16.6	1267	15.9	40	13.7	201	15.6
30-34.9	4000	11.1	4104	10.9	931	11.7	33	11.3	141	11.0
35-39.9	1244	3.4	1347	3.6	305	3.8	4	1.4	46	3.6
>=40	432	1.2	456	1.2	99	1.2	0	0.0	15	1.2
Missing	21101	58.3	22217	59.1	4729	59.3	183	62.5	766	59.5
Current smoker No	6937	19.2	7079	18.8	1514	19.0	52	17.8	242	18.8
Yes	4670	12.9	4795	12.8	995	12.5	35	12.0	143	11.1
Missing	24575	67.9	25720	68.4	5469	68.6	206	70.3	902	70.1